222 related articles for article (PubMed ID: 21420567)
1. New drugs for tuberculosis treatment.
Sánchez F; López Colomés JL; Villarino E; Grosset J
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():47-56. PubMed ID: 21420567
[TBL] [Abstract][Full Text] [Related]
2. New approaches to the treatment of latent tuberculosis.
Sterling TR
Semin Respir Crit Care Med; 2008 Oct; 29(5):532-41. PubMed ID: 18810686
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. New drugs for the treatment of tuberculosis: hope and reality.
Grosset JH; Singer TG; Bishai WR
Int J Tuberc Lung Dis; 2012 Aug; 16(8):1005-14. PubMed ID: 22762423
[TBL] [Abstract][Full Text] [Related]
5. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.
Ena J; Valls V
Clin Infect Dis; 2005 Mar; 40(5):670-6. PubMed ID: 15714411
[TBL] [Abstract][Full Text] [Related]
6. Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
Park SW; Tasneen R; Converse PJ; Nuermberger EL
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874368
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.
Spyridis NP; Spyridis PG; Gelesme A; Sypsa V; Valianatou M; Metsou F; Gourgiotis D; Tsolia MN
Clin Infect Dis; 2007 Sep; 45(6):715-22. PubMed ID: 17712755
[TBL] [Abstract][Full Text] [Related]
9. Treatment of latent tuberculosis infection.
Parekh MJ; Schluger NW
Ther Adv Respir Dis; 2013 Dec; 7(6):351-6. PubMed ID: 24056289
[TBL] [Abstract][Full Text] [Related]
10. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.
Veziris N; Ibrahim M; Lounis N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
Am J Respir Crit Care Med; 2009 Jan; 179(1):75-9. PubMed ID: 18948422
[TBL] [Abstract][Full Text] [Related]
11. [Present and future in the use of anti-tubercular drugs].
Didilescu C; Craiova UM
Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168
[TBL] [Abstract][Full Text] [Related]
12. Latent tuberculosis infection in children: a call for revised treatment guidelines.
Finnell SM; Christenson JC; Downs SM
Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008
[TBL] [Abstract][Full Text] [Related]
13. Rip Van Winkle wakes up: development of tuberculosis treatment in the 21st century.
Burman WJ
Clin Infect Dis; 2010 May; 50 Suppl 3():S165-72. PubMed ID: 20397944
[TBL] [Abstract][Full Text] [Related]
14. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.
Bock NN; Sterling TR; Hamilton CD; Pachucki C; Wang YC; Conwell DS; Mosher A; Samuels M; Vernon A;
Am J Respir Crit Care Med; 2002 Jun; 165(11):1526-30. PubMed ID: 12045127
[TBL] [Abstract][Full Text] [Related]
15. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
[TBL] [Abstract][Full Text] [Related]
16. Rifapentine--a long-acting rifamycin for tuberculosis.
Med Lett Drugs Ther; 1999 Feb; 41(1047):21-2. PubMed ID: 10076594
[No Abstract] [Full Text] [Related]
17. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Williams K; Minkowski A; Amoabeng O; Peloquin CA; Taylor D; Andries K; Wallis RS; Mdluli KE; Nuermberger EL
Antimicrob Agents Chemother; 2012 Jun; 56(6):3114-20. PubMed ID: 22470112
[TBL] [Abstract][Full Text] [Related]
18. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
Zhang T; Li SY; Williams KN; Andries K; Nuermberger EL
Am J Respir Crit Care Med; 2011 Sep; 184(6):732-7. PubMed ID: 21659613
[TBL] [Abstract][Full Text] [Related]
19. Gatifloxacin in combination with rifampicin in a murine tuberculosis model.
Cynamon M; Sklaney MR; Shoen C
J Antimicrob Chemother; 2007 Aug; 60(2):429-32. PubMed ID: 17561504
[TBL] [Abstract][Full Text] [Related]
20. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
